Screener
EBITDA at other companies
Other financials
Where this comes from
Calculated from Inhibrx Biosciences, Inc.’s reported figures.
The source filing: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026. Open the filing →
- Filed
- May 14, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0002007919-26-000027
FAQ
- What is Inhibrx Biosciences, Inc.'s EBITDA?
- Inhibrx Biosciences, Inc. (INBX) reported EBITDA of -$30.39M in Q1 2026.
- How has Inhibrx Biosciences, Inc.'s EBITDA changed year-over-year?
- Inhibrx Biosciences, Inc.'s EBITDA increased by 28.0% year-over-year, from -$42.23M to -$30.39M.
- What is the long-term trend for Inhibrx Biosciences, Inc.'s EBITDA?
- Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s EBITDA has grown at a -22.0% compound annual growth rate (CAGR), from -$218.03M to -$132.54M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Inhibrx Biosciences, Inc.'s ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude